Adicet Bio Stock Is Falling Premarket - Here's Why
Portfolio Pulse from Vandana Singh
Adicet Bio Inc (NASDAQ:ACET) reported safety and efficacy data from its Phase 1 study of ADI-001 for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma (NHL). The trial showed a 71% overall response rate and 63% complete response rate across all dose levels. JMP Securities downgraded Adicet Bio to Market Perform from Market Outperform rating. The company plans to progress the ADI-001 program into a potential pivotal Phase 2 study in post-CAR T large B-cell lymphoma in the first half of 2024.
June 27, 2023 | 11:49 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Adicet Bio's Phase 1 study of ADI-001 for aggressive B-cell NHL shows promising results, but JMP Securities downgrades the stock.
Adicet Bio reported positive results from its Phase 1 study of ADI-001 for aggressive B-cell NHL. However, JMP Securities downgraded the stock to Market Perform from Market Outperform rating, which may negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100